ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

CTMX CytomX Therapeutics Inc

2,15
0,00 (0,00%)
13 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
CytomX Therapeutics Inc CTMX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 2,15 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
2,14 2,07 2,26 2,15 2,15
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
08.4.202414:00GLOBECytomX Therapeutics Announces First Patient Dosed with..
03.4.202414:00GLOBECytomX Therapeutics Announces Nomination of Second Clinical..
21.3.202413:00GLOBECytomX Therapeutics Appoints Dr. Zhen Su to Board of..
18.3.202413:00GLOBECytomX Therapeutics Announces Milestone Achievement in..
11.3.202421:30EDGAR2Form S-8 - Securities to be offered to employees in employee..
11.3.202421:10GLOBECytomX Therapeutics Reports 2023 Financial Results and..
11.3.202421:02EDGAR2Form 8-K - Current report
11.3.202421:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11.3.202411:39IHMARKETNEWSU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s..
04.3.202414:00GLOBECytomX Therapeutics to Report Fourth Quarter and Full Year..
27.2.202414:00GLOBECytomX Therapeutics to Present at Upcoming March Investor..
24.1.202414:00GLOBECytomX Therapeutics Announces FDA Clearance of IND..
20.1.202402:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202402:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202402:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202402:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.1.202414:00GLOBECytomX Therapeutics to Present at the B. Riley Securities..
04.1.202414:00GLOBECytomX Therapeutics Outlines 2024 Company Priorities and..
22.12.202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.12.202322:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.12.202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.12.202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.12.202314:00GLOBECytomX Therapeutics to Present at the 42nd Annual J.P...
20.12.202301:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202301:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202301:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202301:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.11.202322:15GLOBECytomX Therapeutics Reports Third Quarter 2023 Financial..
07.11.202322:05EDGAR2Form 8-K - Current report
07.11.202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01.11.202313:00GLOBECytomX Therapeutics to Present at Upcoming November Investor..
31.10.202313:00GLOBECytomX Therapeutics to Report Third Quarter 2023 Financial..
30.10.202313:00GLOBECytomX Therapeutics to Present Preclinical Data for..
18.10.202322:30GLOBECytomX Therapeutics Presents Preclinical Profile of..
23.9.202301:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.9.202301:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.9.202301:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.9.202322:05GLOBECytomX Therapeutics to Present at Upcoming September..
28.8.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
24.8.202322:05EDGAR2Form 8-K - Current report
16.8.202303:40EDGAR2Form S-3 - Registration statement under Securities Act of..
10.8.202322:05GLOBECytomX Therapeutics to Present at the H.C. Wainwright Immune..
08.8.202322:15GLOBECytomX Therapeutics Reports Second Quarter 2023 Financial..
08.8.202322:08EDGAR2Form 8-K - Current report
08.8.202322:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01.8.202314:00GLOBECytomX Therapeutics to Report Second Quarter 2023 Financial..
20.7.202323:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.7.202323:17EDGAR2Form 3 - Initial statement of beneficial ownership of..
20.7.202315:00GLOBECytomX Therapeutics Announces New Employment Inducement..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock